Melanoma is responsible for most skin cancer-associated deaths globally. The progression
of melanoma is influenced by a number of pathogenic processes. Understanding the …

Immunotherapy has recently emerged as a novel strategy for treating different types of solid
tumors, with promising results. However, still a large fraction of patients do not primarily …

Hypoxia, a condition of low oxygen availability, is a hallmark of tumour microenvironment
and promotes cancer progression and resistance to therapy. Many studies reported the …

Melanoma is increasing in incidence and remains a major public health threat. Although the
disease may be curable when identified early, advanced melanoma is characterized by …

Abstract Purpose of Review Both anti-angiogenesis and immunotherapy are well-
established therapeutic options in solid tumors. Here, we review the rationale as well as …

Malignant melanoma is one of the most common malignancies. Its incidence grows rapidly
at an annual rate of 3− 5%. Although the incidence of melanoma remains low in China, it …

Endostatin is a potent endogenous angiogenic inhibitor with implicated antitumor activity.
However, efficacy of recombinant human endostatin (rhES) in clinical trials is controversial …

Abstract Interferon (IFN) and PEG-IFN are the only drugs approved as adjuvant therapy in
patients with melanoma at high-risk of recurrence after surgical resection. Several clinical …

Angiogenesis is one of the hallmarks of cancer. Several studies have shown that vascular
endothelium growth factor (VEGF) plays a leading role in angiogenesis progression …

Simple Summary Receptor tyrosine kinases (RTKs) have long been demonstrated to play
key roles in melanoma development. RTK activation requires dimerization and intracellular …